Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles

Wilson, Barnabas; Samanta, Malay K.; Santhi, K; Kumar, K.P. Sampath; Paramakrishnan, Nallupillai; Suresh, B.

doi:10.1016/j.ejpb.2008.03.009

Cited by 248 publications

(129 citation statements)

References 56 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…This result is in accordance with earlier findings. 14,33 In addition, it is obvious from the Figure 4 that coating with 1% polysorbate-80 would slightly decrease drug release from the nanoparticles. This might be caused by leakage of drug into the medium during the process of coating.…”

Section: Discussionmentioning

confidence: 99%

“…It is easy to synthesize and scale up, and possesses the abilities of altering the biodistribution of loaded drugs and modulating drug release characteristics. 13,14 Most importantly, many studies have showed that PBCA nanoparticles are able to transport therapeutic agents in significant quantities across the blood-brain barrier into the brain when coated with surfactant polysorbate-80 on their surfaces. These drugs include anticancer agents, 13,15 analgesics, 16 peptides, 17 N-methyl-D-aspartate receptor antagonists, 18 antibiotics, and nonsteroidal anti-inflammatory drugs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles

Tian¹,

Lin²,

Feng³

et al. 2011

IJN

View full text Add to dashboard Cite

Natural Science Foundation of Fujian Province of China; Xiamen Science and Technology Bureau of ChinaBackground: Polybutylcyanoacrylate (PBCA) nanoparticles coated with polysorbate-80 have been extensively proposed for delivering drugs into the animal brain and have shown great potential for therapeutic applications. In this study, we made an attempt to deliver the chemotherapeutic drug, temozolomide, into the brain by using PBCA nanoparticles. The physicochemical characteristics, in vitro release, and brain targeting ability of the drug-loaded nanoparticles were investigated. Results: Our results show that a significantly higher concentration of temozolomide in the form of polysorbate-80-coated PBCA nanoparticles was observed in the brain (P < 0.05) in comparison with the free drug. Conclusion: This study indicates that polysorbate-80 coated PBCA nanoparticles could be a feasible carrier for temozolomide delivery to the brain. It is anticipated that the developed formulation may improve on targeted therapy for malignant brain tumors in the future

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles

Tian¹,

Lin²,

Feng³

et al. 2011

IJN

View full text Add to dashboard Cite

show abstract

“…In vitro release (Wilson et al, 2008) Drug release from nanoparticles was determined in 0.1 N HCl and phosphate buffer pH 6.8 at 37 °C. Nanoparticle suspension (1 mg/mL, 0.5 mL) was placed in a dialysis tube (cellulose membrane, Sigma Chemical Company, USA) and immersed in 10 mL of the release buffer in a 15-mL centrifuge tube and shaken in an incubator shaker set at 100 rpm.…”

Section: Eq (2)mentioning

confidence: 99%

Atorvastatin calcium loaded chitosan nanoparticles: in vitro evaluation and in vivo pharmacokinetic studies in rabbits

Ahmed¹,

Konwar²,

Sengupta³

2015

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

In this study, we prepared atorvastatin calcium (AVST) loaded chitosan nanoparticles to improve the oral bioavailability of the drug. Nanoparticles were prepared by solvent evaporation technique and evaluated for its particle size, entrapment efficiency, zeta potential, in vitro release and surface morphology by scanning electron microscopy (SEM). In addition, the pharmacokinetics of AVST from the optimized formulation (FT5) was compared with marketed immediate release formulation (Atorva ® ) in rabbits. Particle size of prepared nanoparticles was ranged between 179.3 ± 7.12 to 256.8 ± 8.24 nm with a low polydispersity index (PI) value. Zeta potential study showed that the particles are stable with positive values between 13.03 ± 0.32 to 46.90 ± 0.49 mV. FT-IR studies confirmed the absence of incompatibility of AVST with excipient used in the formulations. In vitro release study showed that the drug release was sustained for 48 h. Results of pharmacokinetics study showed significant changes in the pharmacokinetic parameter (2.2 fold increase in AUC) of the optimized formulation as compared to marketed formulation (Atorva ® ). Thus, the developed nanoparticles evidenced the improvement of oral bioavailability of AVST in rabbit model. Uniterms:Atorvastatin calcium/oral bioavailability/experimental study. Atorvastatin calcium/in vitro release. Atorvastatin calcium/pharmacokinetics. Nanoparticles/drugs bioavailability.No presente estudo, preparamos nanopartículas de quitosana com atorvastatina cálcica (AVST) para melhorar a biodisponibilidade oral do fármaco. As nanopartículas foram preparadas pela técnica de evaporação de solvente, avaliando-se a granulometria, a eficiência de encapsulamento, o potencial zeta, a liberação in vitro e a morfologia da superfície, por meio da microscopia eletrônica de varredura (MEV). Além disso, a farmacocinética da formulação otimizada de AVST (FT5) foi comparada com a formulação comercial, de liberação imediata, comercializada (Atorva®), em coelhos. O tamanho das das nanopartículas variou na faixa de 179,3 a 256,8 ± 7,12 ± 8,24 nm, com baixo índice polidispersibilidade (PI). O estudo do potencial Zeta mostrou que as partículas são estáveis, com valores positivos entre 13,03 ± 0,32 a 46,90 ± 0,49 mV. Os estudos de FT-IR confirmaram a ausência de incompatibilidade de AVST com o excipiente utilizado nas formulações. O estudo de liberação in vitro mostrou que liberação sustentada do fármaco por 48 horas. Os resultados do estudo farmacocinético mostraram alterações significativas nos parâmetros (aumento de 2,2 vezes na ASC) da formulação otimizada em relação à comercializada (Atorva® ). Assim, o desenvolvimento de nanopartículas evidenciou a melhora da biodisponibilidade oral de AVST em coelhos.Uniterms: Atorvastatina cálcica/biodisponibilidade oral/estudo experimental. Atorvastatina cálcica/ liberação in vitro. Atorvastatina cálcica/farmacocinética. Nanopartículas/biodisponibilidade de fármacos.

show abstract

“…In a rat model of brain tumor, survival time was significantly increased in rats treated with Gem-PBCA + PS80 as compared to those treated with free gemcitabine. 146 Polymeric nanoparticles coated with polysorbate 80 have been used successfully to transport tacrine 147 and the antitumor agent doxorubicin 148 to the brain. It has been shown in vitro and in vivo that polymeric nanoparticles penetrated the endothelium of the brain, and the preparation accumulated in the brain resulting in strong antitumor effects (see details in the review by Kreuter and Gelperina).…”

mentioning

confidence: 99%

Nanoscale drug delivery systems and the blood–brain barrier

Alyautdin¹,

Khalin²,

Nafeeza³

et al. 2014

IJN

114

View full text Add to dashboard Cite

The protective properties of the blood–brain barrier (BBB) are conferred by the intricate architecture of its endothelium coupled with multiple specific transport systems expressed on the surface of endothelial cells (ECs) in the brain’s vasculature. When the stringent control of the BBB is disrupted, such as following EC damage, substances that are safe for peripheral tissues but toxic to neurons have easier access to the central nervous system (CNS). As a consequence, CNS disorders, including degenerative diseases, can occur independently of an individual’s age. Although the BBB is crucial in regulating the biochemical environment that is essential for maintaining neuronal integrity, it limits drug delivery to the CNS. This makes it difficult to deliver beneficial drugs across the BBB while preventing the passage of potential neurotoxins. Available options include transport of drugs across the ECs through traversing occludins and claudins in the tight junctions or by attaching drugs to one of the existing transport systems. Either way, access must specifically allow only the passage of a particular drug. In general, the BBB allows small molecules to enter the CNS; however, most drugs with the potential to treat neurological disorders other than infections have large structures. Several mechanisms, such as modifications of the built-in pumping-out system of drugs and utilization of nanocarriers and liposomes, are among the drug-delivery systems that have been tested; however, each has its limitations and constraints. This review comprehensively discusses the functional morphology of the BBB and the challenges that must be overcome by drug-delivery systems and elaborates on the potential targets, mechanisms, and formulations to improve drug delivery to the CNS.

show abstract

Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles

Cited by 248 publications

References 56 publications

Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles

Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles

Atorvastatin calcium loaded chitosan nanoparticles: in vitro evaluation and in vivo pharmacokinetic studies in rabbits

Nanoscale drug delivery systems and the blood–brain barrier

Contact Info

Product

Resources

About

Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles

Cited by 248 publications

References 56 publications

Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles

Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles

Atorvastatin calcium loaded chitosan nanoparticles: in vitro evaluation and in vivo pharmacokinetic studies in rabbits

Nanoscale drug delivery systems and the blood&ndash;brain barrier

Contact Info

Product

Resources

About

Nanoscale drug delivery systems and the blood–brain barrier